|Author(s)/Faculty: Justis P. Ehlers, MD; Rishi P. Singh, MD|
|Source: Healio Education Lab – Ophthalmology|
CME Provided By: Vindico Medical Education
Age-related macular degeneration (AMD) is a leading cause of irreversible blindness and visual impairment. As prevalence of AMD continues to increase, it is estimated that nearly 3 million individuals in the United States will develop AMD by 2020. The integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapies into therapeutic protocols has significantly improved the prognosis for patients with AMD. Unfortunately, initial vision gains are not always maintained; however, continued evaluation of anti-VEGF therapies and treatment protocols are now providing visual acuity gains with long-term therapy. In this educational activity, experts in the field review intravitreal anti-VEGF treatment protocols, discuss outcomes from pinnacle clinical studies, and evaluate recent studies that demonstrate visual acuity benefits with long-term anti-VEGF therapy.
LINK TO CME: Healio Education